Blesius, Aurore <br/><br/>
Are tyrosine kinase inhibitors still active in patients with metastatic renal cell carcinoma previously treated with a tyrosine kinase inhibitor and everolimus? Experience of 36 patients treated in France in the RECORD-1 Trial.  [electronic resource] 

 -  Clinical genitourinary cancer  Jun 2013 
 - 128-33 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1938-0682 
<br/><br/><label>Standard No.: </label>10.1016/j.clgc.2012.12.001  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Agents--therapeutic use<br/>Benzimidazoles--therapeutic use<br/>Carcinoma, Renal Cell--drug therapy<br/>Disease-Free Survival<br/>Everolimus<br/>Female<br/>France<br/>Humans<br/>Indoles--therapeutic use<br/>Kidney Neoplasms--drug therapy<br/>Male<br/>Middle Aged<br/>Niacinamide--analogs & derivatives<br/>Phenylurea Compounds--therapeutic use<br/>Protein Kinase Inhibitors--therapeutic use<br/>Pyrroles--therapeutic use<br/>Quinolones--therapeutic use<br/>Salvage Therapy<br/>Sirolimus--analogs & derivatives<br/>Sorafenib<br/>Sunitinib<br/>TOR Serine-Threonine Kinases--antagonists & inhibitors<br/>Treatment Failure<br/>Treatment Outcome